Shares of Eli Lilly (LLY) declined 2.3%. Monday, after a research undertaken by the medicine producer discovered that people who use its weight-loss therapies may gain weight after stopping the drugs.
The researchers looked at those who took Zepbound for 36 weeks, which was licensed by the Food and Drug Administration (FDA) last month to treat patients who were fat or overweight. They then had half of the people take it for another 52 weeks while the other half got a placebo.
Patients who stayed on Zepbound for the longer duration lost an extra 5.5% on average. Those who took the placebo, on the other hand, gained an average of 14% more weight.
According to Dr. Jeff Emmick, senior vice president of product development at Lilly, many patients, clinicians, and the general public do not often understand that obesity is a chronic disease that often requires continuous treatment, but rather that it ends once weight targets are accomplished. He went on to say that studies like this one demonstrate that “continued therapy can help people living with obesity maintain their weight loss.”
Tirzepatide, the active ingredient in Zepbound, is also contained in Lilly’s other popular weight reduction and diabetic medication, Mounjaro.
Eli Lilly shares reached an all-time high after Zepbound obtained regulatory approval, and despite Monday’s dip, the stock has gained around 60% this year.